Syntis Bio Launches to Revolutionize Oral Therapy for Obesity, Diabetes and Rare Diseases by Unlocking the Full Therapeutic Potential of the Small Intestine

Lead program SYNT-101 now in human trials to validate potential as a once-daily oral obesity therapyOrphan pediatric portfolio acquired from Codexis expands pipeline with first-in-class oral enzyme re

BusinesswireJun 11 07:00 ET

Codexis Initiated at Overweight by Cantor Fitzgerald

Codexis Initiated at Overweight by Cantor Fitzgerald

Dow JonesMay 30 09:03 ET

Cantor Fitzgerald Starts Codexis With Overweight Rating, $11 Price Target

Codexis (CDXS) has an average rating of buy and price targets ranging from $3 to $11, according to analysts polled by Capital IQ. Price: 3.3473, Change: +0.16, Percent Change: +4.93

MT NewswiresMay 30 08:40 ET

Codexis to Participate in Jefferies Global Healthcare Conference

REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Global Healthcare Conference, being held

GlobeNewswireMay 22 16:25 ET

Codexis to Participate in TD Cowen 2nd Annual Sustainability Week

REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled, "Sustainable API

GlobeNewswireMay 20 16:05 ET

Stifel Nicolaus Reaffirms Their Buy Rating on Codexis (CDXS)

TipRanksMay 20 07:55 ET